en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Topic › Persistence, Stability And Measurement — Research Overview

Persistence, Stability And Measurement — Research Overview

By Editorial Desk · published 2025-12-16 · last reviewed 2026-01-25 · Topic

Mod GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Cjc-1295 at a glance

PropertyValueNotes
Molecular massApproximately 3.4 to 3.6 kDaDepends on whether the affinity complex is attached
AppearanceWhite to off-white lyophilized powderFreeze-dried solid, often in a sealed vial
SolubilitySoluble in water and aqueous buffersDissolution rate varies with pH and buffer salt
Typical storageBelow minus 20 degrees Celsius, dry and darkDissolved material is usually kept cold and used promptly
Common analytical methodsReversed-phase HPLC and mass spectrometryPeptide mapping and amino acid analysis add sequence detail

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Analytical Measurement And Stability

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

CJC-1295 Background and Mechanism

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

Analytical Characterization and Storage

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Reference notes

=== Discovery of biomolecules through metagenomics === The advances in modern sequencing technologies in the late 1990s allowed scientists to investigate DNA of communities of organisms in their natural environments ("eDNA"), without culturing individual species in the lab. This metagenomic approach enabled scientists to study a wide selection of organisms that were previously not characterized due in part to an incompetent growth condition. Sources of eDNA include soils, ocean, subsurface, hot springs, hydrothermal vents, polar ice caps, hypersaline habitats, and extreme pH environments. Of the many applications of metagenomics, researchers such as Jo Handelsman, Jon Clardy, and Robert M. Goodman, explored metagenomic approaches toward the discovery of biologically active molecules such as antibiotics.

A trackway consisting of four footprints discovered near Marmarth, North Dakota in 2025 and described in 2026 have been attributed to an adult Tyrannosaurus based on the shape and size of the tracks, which measure 1 m (3.3 ft). The set of tracks suggests a stride length of 4 m (13 ft) for the animal that made them, with speed estimates of 1.5–2 meters per second (3.4-4.5 mph). The fluvial environment of the upper Hell Creek Formation, from which the footprints were unearthed may explain the significant scarcity of trackways and the uncommon nature of theropod footprints in the formation in general. Three of the footprints are expected to be recovered in autumn of 2026 to be displayed at the Denver Museum of Nature and Science.

Despite its sedating action, mirtazapine is also believed to be capable of this, so in the United States and certain other countries, it carries a black box label warning of these potential effects, especially for people under the age of 25. Mirtazapine may induce arthralgia (non-inflammatory joint pain). A case report published in 2000 noted an instance in which mirtazapine counteracted the action of clonidine, causing a dangerous rise in blood pressure. In a study comparing 32 antidepressants of all pharmacological classes, mirtazapine was one of the antidepressants most likely to cause nightmare disorder, sleepwalking, restless legs syndrome, night terrors and sleep paralysis. Mirtazapine has been associated with an increased risk of death compared to other antidepressants in several studies. However, it is more likely that the residual differences between people prescribed mirtazapine rather than a selective serotonin reuptake inhibitor account for the difference in risk of mortality.

Sources: en.wikipedia.org

Reference notes

The literature review in a 2016 study includes mentions of ethnic factionalism, supportive foreign governments, leader inexperience, slow growth, commodity price shocks, and poverty. Coups have been found to appear in environments that are heavily influenced by military powers. Multiple of the above factors are connected to military culture and power dynamics. These factors can be divided into multiple categories, with two of these categories being a threat to military interests and support for military interests. If interests go in either direction, the military will find itself either capitalizing off that power or attempting to gain it back. Oftentimes, military spending is an indicator of the likelihood of a coup taking place. Nordvik found that about 75% of coups that took place in many different countries rooted from military spending and oil windfalls.

Mephedrone acts as a potent substrate for monoamine transporters, including the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). It inhibits the reuptake of these neurotransmitters and promotes their release. The drug induces a rapid and significant increase in extracellular levels of dopamine, serotonin, and norepinephrine. This effect is more pronounced for serotonin compared to dopamine, which distinguishes mephedrone from much of the other psychostimulants. The pharmacodynamic profile of mephedrone is often compared to MDMA and methamphetamine. Like MDMA, it has a greater effect on serotonin than dopamine release. Similar to methamphetamine, it causes rapid dopamine release. Mephedrone has been found to be a full releaser of serotonin but a partial releaser of dopamine. In addition to induction of monoamine release via the monoamine transporters, mephedrone shows significant affinity for various receptors, including the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and α2-adrenergic receptors, as well as the trace amine-associated receptor 1 (TAAR1). Mephedrone is a potent and near-full agonist of the serotonin 5-HT2A receptor, whereas it was inactive as an agonist of the serotonin 5-HT2B receptor. Mephedrone binds to and activates the rat and mouse TAAR1 with micromolar potencies, but is not an agonist of the human TAAR1 (EC50Tooltip half-maximal effective concentration > 30 μM).

Protactinium(IV) forms a tetrahedral complex tetrakis(cyclopentadienyl)protactinium(IV) (or Pa(C5H5)4) with four cyclopentadienyl rings, which can be synthesized by reacting protactinium(IV) chloride with Be(C5H5)2. One ring can be substituted with a halide atom. Another organometallic complex is the golden-yellow bis(π-cyclooctatetraene) protactinium, or protactinocene (Pa(C8H8)2), which is analogous in structure to uranocene. There, the metal atom is sandwiched between two cyclooctatetraene ligands. Similar to uranocene, it can be prepared by reacting protactinium tetrachloride with dipotassium cyclooctatetraenide (K2C8H8) in tetrahydrofuran.

=== Enzymatic activity of lactoferrin === Lactoferrin hydrolyzes RNA and exhibits the properties of pyrimidine-specific secretory ribonucleases . In particular, by destroying the RNA genome, milk RNase inhibits reverse transcription of retroviruses that cause breast cancer in mice. Parsi women in West India have the milk RNase level markedly lower than in other groups, and their breast cancer rate is three times higher than average. Thus, ribonucleases of milk, and lactoferrin in particular, might play an important role in pathogenesis.

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between the forms with and without a drug affinity complex?

The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.

Is CJC-1295 the same as MOD GRF 1-29?

In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.

How is the compound identified in a laboratory?

Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network